Fundraising FoxTullis Health Investors — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Ophirex is a biotech company developing varespladib, an investigational oral capsule intended to treat snakebite envenomation by inactivating a key venom toxin found in most snake species.
BiotechDeep TechHealthtechCorte Madera, US
Jerry Harrison(Co-founder; Director)Matthew R. Lewin(Founder and Board Member)inJeremy Gowler(Chief Executive Officer & Board Director)inSara Carter(Executive)Timothy Platts-Mills(Executive)Dotson(Finance leader (Controller/Finance))
.jpg)
Board seatCurt LaBelle· per SEC Form D · $35M raise · filed Mar 2022
Co-investorsGlobal Health Investment Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.